Home / About LSDs / GM1 Gangliosidosis
GM1 Gangliosidosis: Types, Symptoms and Support in India
GM1 gangliosidosis is a rare inherited disorder in which a fatty substance builds up in nerve cells of the brain and spinal cord and, in babies, in other organs and the bones. There is no approved treatment yet, but supportive care, genetic counselling and clinical trials can help families.
Key facts
Cause
Deficiency of the enzyme beta-galactosidase (GLB1 gene)
Inheritance
Autosomal recessive
Mainly affects
Brain and spinal cord; in babies also the liver, spleen, heart and bones
How common
About 1 in 100,000 to 200,000 births worldwide; among the more commonly diagnosed LSDs in India
Treatment
Supportive care; new therapies are being tested in clinical trials
On this page:
Overview
What is GM1 gangliosidosis?
GM1 gangliosidosis is a rare genetic disorder that progressively damages nerve cells in the brain and spinal cord. It is caused by a deficiency of the enzyme beta-galactosidase, which normally breaks down a fatty substance called GM1 ganglioside and certain complex sugars.
Without the enzyme, GM1 ganglioside builds up to harmful levels in nerve cells, which gradually stop working. In the infantile form, related substances also build up in the liver, spleen, heart and bones.
GM1 gangliosidosis is closely related to the GM2 gangliosidoses, Tay-Sachs and Sandhoff disease. The same gene also causes a rare form of Morquio syndrome (MPS IVB), which mainly affects the bones.
Why a diagnosis matters
A confirmed diagnosis opens doors
Even without an approved treatment, knowing the exact diagnosis helps. It means the right supportive care, genetic counselling, testing in future pregnancies and, for some families, a place in a clinical trial. The trials list on this page shows studies recruiting in India.
GM1 gangliosidosis in India
GM1 gangliosidosis is estimated to affect about 1 in 100,000 to 200,000 newborns worldwide. In Indian hospital studies, it is one of the more commonly diagnosed lysosomal storage disorders after Gaucher disease and MPS, especially in young children who are losing skills they had learned.
Marriage between close relatives (consanguinity) raises the chance of inherited conditions like GM1 gangliosidosis. Carrier testing and genetic counselling help families understand their risk.
Did you know?
GM1 gangliosidosis is one of the more commonly diagnosed lysosomal storage disorders in Indian children.
An early diagnosis helps families plan care and find out about clinical trials.
Types of GM1 gangliosidosis
Doctors describe three types, based on the age at which symptoms begin. The earlier they begin, the faster the disease usually progresses.
Type I (infantile)
The most common and most severe form. Symptoms begin before 6 months of age, with floppy muscles, loss of skills, an enlarged liver and spleen, coarse facial features, bone changes and sometimes an enlarged heart. A cherry-red spot may be seen in the eye. Most children live only into early childhood.
Type II (late-infantile and juvenile)
Symptoms begin between about 7 months and 10 years of age, with loss of skills already learned, clumsiness, seizures and learning difficulties. The liver and spleen are usually not enlarged. Children often live into late childhood or adolescence.
Type III (adult or chronic)
A milder form that begins in later childhood, adolescence or early adulthood. It mainly causes abnormal muscle tightening (dystonia), slurred speech, walking difficulties and changes in the spine. Many people live into adulthood.
Signs and symptoms
Symptoms of GM1 gangliosidosis
Symptoms depend on the type. In babies with the infantile form, they may include:
- Weak, floppy muscles and loss of skills such as holding up the head or sitting
- An enlarged liver and spleen, causing a swollen abdomen
- Coarse facial features and thickened gums
- Bone and spine changes, and stiff joints
- A cherry-red spot at the back of the eye, and loss of vision
- Seizures, feeding difficulty and frequent chest infections
When to see a doctor
Consult a doctor, ideally a paediatric neurologist or geneticist, if your child has:
- Loss of skills already learned, or slowing development
- Floppy muscles with an enlarged liver or spleen
- Coarse facial features or unusual bone changes
- Seizures or vision problems
An eye doctor may find a cherry-red spot at the back of the eye, a clue shared with Tay-Sachs and Sandhoff disease.
Causes
What causes GM1 gangliosidosis?
GM1 gangliosidosis is caused by changes (mutations) in the GLB1 gene, which gives the body instructions to make the enzyme beta-galactosidase.
When the enzyme is missing or works poorly, GM1 ganglioside builds up in nerve cells, and related substances build up in other tissues. People with some remaining enzyme activity tend to have the later-onset types.
How it is inherited
- It is inherited in an autosomal recessive pattern.
- Parents of an affected child are usually healthy carriers of one faulty copy of the gene.
- When both parents are carriers, each pregnancy has a 1 in 4 (25%) chance of an affected child.
- Genetic counselling and carrier testing can help families understand their risk and plan.
How is GM1 gangliosidosis diagnosed?
A blood test can confirm GM1 gangliosidosis, and a genetic test identifies the cause.
01
Enzyme test
A blood test, often on a dried blood spot, measures beta-galactosidase activity. Very low activity confirms GM1 gangliosidosis or the related MPS IVB.
02
Genetic test
Confirms changes in the GLB1 gene. It also helps test family members and plan future pregnancies.
03
Urine tests
Raised levels of complex sugars (oligosaccharides) and keratan sulfate in the urine support the diagnosis.
04
Eye, bone and brain checks
An eye examination for a cherry-red spot, X-rays of the bones, a brain MRI and a heart scan show how the disease is affecting the body.
Care and treatment for GM1 gangliosidosis
There is no cure and no approved disease-specific treatment yet. Care focuses on comfort, quality of life and support for the family.
Supportive care
A team of specialists helps manage symptoms as the disease progresses.
This can include
- Medicines to control seizures
- Feeding support, including feeding tubes
- Chest physiotherapy and treatment of infections
- Physiotherapy and orthopaedic care
Palliative care and family support
Palliative care focuses on comfort and quality of life for the child and the whole family. It can be given alongside other care, at home or in hospital, and includes emotional support for parents and siblings.
Research and clinical trials
Gene therapy, and substrate reduction therapy, which aims to reduce the build-up of GM1 ganglioside, are being studied in clinical trials. See the list of studies recruiting in India below.
Genetic counselling is an important part of care. It helps families understand the chance of GM1 gangliosidosis in future children and the testing options available.
Clinical trials and studies in India
Studies of GM1 gangliosidosis that are recruiting, or about to recruit, in India. This list updates automatically every day.
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 GangliosidosisSites in India: Ernākulam, New Delhi, Jaipur, Vellore
Last checked 5 November 2026 on ClinicalTrials.gov. Always talk to your doctor before joining a study.
Accessing treatment in India
Getting care and support
Caring for a child with GM1 gangliosidosis is demanding, emotionally and financially. These are the main sources of help.
Government support (NPRD)
The National Policy for Rare Diseases supports diagnosis, genetic counselling and care for rare diseases at designated Centres of Excellence (COEs). Ask your COE what help is available for your family.
- Visit your nearest COE with all medical reports
- Ask about genetic counselling and testing for the family
- Financial assistance is subject to approval
Other sources of help
- State government health schemes
- Corporate social responsibility (CSR) funding
- Crowdfunding through the government rare disease portal
- Palliative care services near you
How LSDSS helps
- Connects patients with COEs and specialists
- Guides families through funding applications
- Shares updates on support programmes
- Brings patients and caregivers together
Frequently asked questions
Answers to common questions about GM1 gangliosidosis.
Still have a question?
A rare inherited disorder in which a deficiency of the enzyme beta-galactosidase causes a fatty substance, GM1 ganglioside, to build up in nerve cells of the brain and spinal cord, gradually damaging them.
There are three types, named after the age at which symptoms begin: type I (infantile, before 6 months), type II (late-infantile and juvenile, from about 7 months to 10 years) and type III (adult or chronic, from later childhood onwards).
It depends on the type. Most children with the infantile form live only into early childhood, often until about 2 or 3 years of age. Children with type II often live into late childhood or adolescence. People with type III usually live into adulthood.
Not yet. There is no approved treatment that stops the disease, but supportive and palliative care can ease symptoms. Gene therapy and other treatments are being studied in clinical trials.
It is autosomal recessive. A child is affected when both parents pass on a faulty copy of the GLB1 gene. When both parents are carriers, each pregnancy has a 1 in 4 chance of an affected child.
Both are gangliosidoses with similar effects on the brain, including a cherry-red spot in the eye. In GM1 gangliosidosis, a lack of beta-galactosidase causes GM1 ganglioside to build up. In Tay-Sachs and Sandhoff disease, a lack of hexosaminidase causes GM2 ganglioside to build up. Babies with GM1 gangliosidosis are also more likely to have an enlarged liver and spleen and bone changes.
First, visit your nearest Centre of Excellence (COE) with all medical reports to be evaluated and to get genetic counselling. Second, register with LSDSS for support and to connect with other families.
Other lysosomal storage disorders
LSDSS supports patients and families living with all lysosomal storage disorders.
A fatty substance builds up in nerve cells of the brain and spinal cord.
Sulfatides build up and damage the protective covering of nerves.
Caring for a child with GM1 gangliosidosis?
Register with LSDSS for guidance, support and the latest updates. You are not alone.
This page is for general information and awareness only. It does not replace advice from a qualified doctor. Last reviewed: November 2026.